Cyclopharm Limited
Informe acción ASX:CYC
Capitalización de mercado: AU$150.0m
Cyclopharm Dividendos y recompras
Dividendo controles de criterios 0/6 Cyclopharm no paga actualmente dividendo.
Información clave
0%
Rentabilidad por dividendo
-16.1%
Rendimiento de la recompra
Rendimiento total para el accionista -16.1% Rendimiento futuro de los dividendos 0.7% Crecimiento de los dividendos n/a Próxima fecha de pago de dividendos n/a Fecha ex dividendo n/a Dividendo por acción AU$0.010 Ratio de pago 0%
Últimas actualizaciones de dividendos y recompras
Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023 Aug 22
Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023 Feb 20
Cyclopharm Limited Declares an Unfranked Dividend for the Half Year Ended June 30, 2022, Payable on 12 September 2022 Aug 17
Cyclopharm Limited Announces Dividend for Period of Six Months Ended December 31, 2021, Payable on April 12, 2022 Feb 24
Mostrar todas las actualizaciones
New minor risk - Market cap size Nov 12
Non-Executive Director recently bought AU$51k worth of stock Oct 03
Consensus revenue estimates fall by 13% Sep 02
First half 2024 earnings released: AU$0.078 loss per share (vs AU$0.032 loss in 1H 2023) Aug 31
Forecast breakeven date pushed back to 2026 Aug 28
New minor risk - Shareholder dilution May 31 Cyclopharm Limited has completed a Follow-on Equity Offering in the amount of AUD 20.000001 million. May 29
Cyclopharm Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.
New minor risk - Market cap size May 20
Consensus revenue estimates fall by 14% May 07
Cyclopharm Limited, Annual General Meeting, May 27, 2024 Mar 25
Full year 2023 earnings: EPS exceeds analyst expectations Feb 29
Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director Feb 20
Consensus EPS estimates fall by 11% Dec 06
CEO, MD exercised options to buy AU$402k worth of stock. Dec 02
What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash Oct 28
Forecast breakeven date pushed back to 2025 Oct 25
First half 2023 earnings released: AU$0.032 loss per share (vs AU$0.028 loss in 1H 2022) Aug 23
Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023 Aug 22
Consensus estimates of losses per share improve by 13% Apr 26
Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount? Apr 18
Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth Mar 31
Consensus EPS estimates fall by 153% Feb 28
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 21
Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023 Feb 20
Less than half of directors are independent Nov 16
Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth Oct 17
Less than half of directors are independent Sep 28
Cyclopharm Limited Appoints Gregory King as A Non-Executive Director Sep 27
Cyclopharm Limited Appoints Kevin Barrow as A Nonexecutive Director Sep 01
First half 2022 earnings released: AU$0.028 loss per share (vs AU$0.045 loss in 1H 2021) Aug 18
Cyclopharm Limited Declares an Unfranked Dividend for the Half Year Ended June 30, 2022, Payable on 12 September 2022 Aug 17
Consensus revenue estimates increase by 10% Jul 15
Cyclopharm Limited Announces Independent Multicentre Study Highlights the Benefits of Technegas in Diagnosing Pulmonary Embolism in Growing Covid-19 Patient Population Jul 07
Cyclopharm Limited Provides Sales Guidance for the Half Year Ended 30 June 2022 Jul 05
Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth Jun 09
Cyclopharm Limited Announces Technegas Used in Diagnosing Long COVID May 24
Full year 2021 earnings: Revenues exceed analyst expectations Apr 05
Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher Mar 06
Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation Mar 02
Consensus revenue estimates increase by 14% Mar 02
Forecast to breakeven in 2024 Mar 02
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 24
Cyclopharm Limited Announces Dividend for Period of Six Months Ended December 31, 2021, Payable on April 12, 2022 Feb 24
Cyclopharm Limited Provides Earnings Guidance for the Full Year 2021 Jan 24
Less than half of directors are independent Dec 07
We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth Oct 22
First half 2021 earnings released: AU$0.045 loss per share (vs AU$0.074 loss in 1H 2020) Aug 26
Cyclopharm Limited Provides Unaudited Revenue Guidance for the First Half of 2021 Jul 03
Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates Jun 29
Consensus revenue estimates fall to AU$16.5m Jun 29
Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being Apr 27
Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019) Apr 04
Cyclopharm Limited provides Confirmation of Technegas USFDA Timetable Mar 12
Analysts increase revenue estimates to AU$18.6m Mar 04
Cyclopharm Limited, Annual General Meeting, May 04, 2021 Mar 03
Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic Mar 01
Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019) Feb 27
Revenue beats expectations, earnings disappoint Feb 27
Cyclopharm Limited Provides Update on USFDA Approval to Distribute Technegas in the USA in 2021 Feb 26
Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment Feb 07
New 90-day high: AU$3.10 Jan 15
Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders? Jan 02
We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate Dec 06
New 90-day high: AU$2.63 Dec 03
Cyclopharm Limited Announces A New Research Collaboration with Mcmasters University Sep 21
New 90-day high - AU$1.59 Sep 15
First half earnings released Aug 26
Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de CYC han sido estables en el pasado.
Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de CYC han aumentado.
Rentabilidad por dividendo vs. Mercado Rentabilidad por dividendo de Cyclopharm vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de CYC con la del mercado? Segmento Rentabilidad por dividendo Empresa (CYC) 0% Suelo de mercado 25% (AU) 2.6% Techo de mercado 25% (AU) 6.1% Media de la industria (Medical Equipment) 1.6% Analista de previsiones (CYC) (hasta 3 años) 0.7%
Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de CYC en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Alto dividendo: No es posible evaluar la rentabilidad por dividendo de CYC en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Pago de beneficios a los accionistas
Cobertura de los beneficios: CYC no paga un dividendo notable para el mercado Australian.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que CYC no ha comunicado ningún pago.
Descubre empresas que pagan buenos dividendos Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
